Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Research & Development: 2018-2025

Historic Research & Development for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $23.3 million.

  • Arcturus Therapeutics Holdings' Research & Development fell 40.55% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year decrease of 30.04%. This contributed to the annual value of $195.2 million for FY2024, which is 1.57% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Research & Development of $23.3 million as of Q3 2025, which was down 21.35% from $29.6 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Research & Development registered a high of $58.7 million during Q2 2024, and its lowest value of $23.3 million during Q3 2025.
  • For the 3-year period, Arcturus Therapeutics Holdings' Research & Development averaged around $43.2 million, with its median value being $43.8 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 532.18% in 2021, then plummeted by 49.58% in 2025.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Research & Development stood at $32.6 million in 2021, then fell by 17.32% to $27.0 million in 2022, then soared by 35.73% to $36.6 million in 2023, then rose by 19.55% to $43.8 million in 2024, then plummeted by 40.55% to $23.3 million in 2025.
  • Its Research & Development stands at $23.3 million for Q3 2025, versus $29.6 million for Q2 2025 and $34.9 million for Q1 2025.